Renal manifestations of the antiphospholipid syndrome

被引：1

作者：

D'Cruz D. ^{[1
]}

机构：

[1] The Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital

来源：

Current Rheumatology Reports | 2009年 / 11卷 / 1期

关键词：

Systemic Lupus Erythematosus; Systemic Lupus Erythematosus Patient; Lupus Nephritis; Renal Artery Stenosis; Lupus Anticoagulant;

D O I：

10.1007/s11926-009-0008-2

中图分类号：

学科分类号：

摘要：

The antiphospholipid syndrome is characterized by recurrent arterial and venous thromboses and pregnancy morbidity in association with antiphospholipid antibodies. Recurrent thrombotic events are associated with significant morbidity and mortality. Renal involvement encompasses the whole renal vasculature and may lead to proteinuria, renal impairment, hypertension, and end-stage renal failure. Renal involvement is especially difficult to distinguish from glomerulonephritis when the antiphospholipid syndrome develops in patients with systemic lupus erythematosus. This article reviews the diagnosis and treatment of the major features of this syndrome, with particular reference to the kidney. © Springer Science+Business Media, LLC 2009.

引用

页码：52 / 60

页数：8

共 69 条

[1]

Hughes G.R., Thrombosis, abortion, cerebral disease, and the lupus anticoagulant, BMJ, 287, pp. 1088-1089, (1983)

[2]

Harris E.N., Gharavi A.E., Boey M.L., Et al., Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus, Lancet, 2, pp. 1211-1214, (1983)

[3]

Brandt J.T., Triplett D.A., Alving B., Scharrer I., Criteria for the diagnosis of lupus anticoagulants: An update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH, Thromb Haemost, 74, pp. 1185-1190, (1995)

[4]

Cervera R., Khamashta M.A., Font J., Et al., Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus, Medicine (Baltimore), 72, pp. 113-124, (1993)

[5]

Cervera R., Piette J.C., Font J., Et al., Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis Rheum, 46, pp. 1019-1027, (2002)

[6]

Perez-Vazquez M.E., Villa A.R., Drenkard C., Et al., Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus, J Rheumatol, 20, pp. 437-442, (1993)

[7]

Wilson W., Gharavi A., Koike T., Et al., International consensus statement on preliminary classification for definite antiphospholipid syndrome. Report of an International Workshop, Arthritis Rheum, 42, pp. 1309-1311, (1999)

[8]

Lockshin M.D., Sammaritano L.R., Schwartzman S., Validation of the Sapporo criteria for antiphospholipid syndrome, Arthritis Rheum, 43, pp. 440-443, (2000)

[9]

Miyakis S., Lockshin M.D., Atsumi T., Et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, pp. 295-306, (2006)

[10]

Shah N.M., Khamashta M.A., Atsumi T., Hughes G.R., Outcome of patients with anticardiolipin anti-bodies: A 10 year follow up of 52 patients, Lupus, 7, pp. 3-6, (1998)

← 1 2 3 4 5 6 7 →